在现实世界炎症性肠病队列中使用类固醇的模式和预测因素
Rodger Wu1,2,3,4, Consuelo Rivas1, Wai Kin Su1,2,3
1Department of Gastroenterology and Hepatology Liverpool Hospital Sydney New South Wales Australia.
JGH open : an open access journal of gastroenterology and hepatology
|December 11, 2025
概括
在炎症性肠病 (IBD) 中使用类固醇影响了超过18%的患者,女性和年轻人暴露率更高. 优化治疗,特别是对于性结肠炎患者,可以减少对类固醇的依赖.
科学领域:
- 胃肠病学 胃肠病学
- 临床药理学 临床药理学
- 现实世界的证据研究研究.
背景情况:
- 在炎症性肠病 (IBD) 中使用类固醇是常见的,但与不良影响有关.
- 在现实世界IBD队列中使用类固醇的模式尚不清楚.
- 暴露于类固醇往往意味着疾病的控制不足.
研究的目的:
- 在一大群IBD患者中检查类固醇使用的模式和预测因素.
- 为了确定与类固醇暴露相关的人口和疾病相关因素.
- 在IBD管理中为减少类固醇依赖的策略提供信息.
主要方法:
- 在5436名IBD患者中分析了3年的类固醇暴露窗口.
- 类固醇使用按持续时间 (短期,中度,长期) 和最近情况进行分类.
- 多变量后勤回归评估了与人口和疾病因素的关联.
主要成果:
- 18.3%的患者在3年内接触过类固醇.
- 女性和年轻成年人 (20-29岁) 长期/最近使用类固醇的几率更高.
- 与性结肠炎相比,克罗恩病与长期/最近使用的几率较低有关.
结论:
- 在IBD中使用类固醇相对适度,超过80%的患者在3年内没有暴露.
- 建议主动优化治疗,特别是对于年轻患者和性结肠炎患者.
- 减少类固醇暴露可以减轻相关的不良影响,并改善疾病管理.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
408
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
408
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
614
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
614
Inflammatory Bowel Disease II: Crohn's Disease
915
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
915
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
459
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
459
Inflammatory Bowel Disease I: Ulcerative Colitis
859
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
859
Inflammatory Bowel Disease IV: Pharmacological Management
445
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
445


